525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775

525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 33; pp. S785 - S786
Main Authors: Makker, V., Colombo, N., Casado Herraez, A., Monk, B.J., Mackay, H., Santin, A.D., Miller, D.S., Moore, R.G., Baron-Hay, S.E., Ray-Coquard, I.L., Shapira-Frommer, R., Ushijima, K., Yonemori, K., Kim, Y.M., Guerra Alia, E.M., Sanli, U.A., Huang, J., McKenzie, J., Barresi, G., Lorusso, D.
Format: Journal Article
Language:English
Published: 01-09-2022
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
DOI:10.1016/j.annonc.2022.07.653